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Abstract 
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated 
cystoid macular oedema that responded on two separate occasions to intravitreal injections 
of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibi-
zumab. This unique case would support a trial of intravitreal aflibercept for the treatment of 
RP-associated cystoid macular oedema. Case Presentation: A 38-year-old man from Dubai, 
United Arab Emirates, presented to the UK with a 3-year history of bilateral RP-associated 
cystoid macular oedema. Previous treatment with topical dorzolamide, oral acetazolamide, 
and intravitreal ranibizumab had demonstrated only minimal reduction of cystoid macular 
oedema. Following re-confirmation of the diagnosis by clinical examination and optical co-
herence tomography imaging, bilateral loading doses of intravitreal aflibercept were given. 
Central macular thickness reduced and the patient returned to Dubai. After 6 months, the 
patient was treated with intravitreal ranibizumab due to re-accumulation of fluid and the 
unavailability of aflibercept in Dubai. Only minimal reduction of central macular thickness 
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was observed. Once available in Dubai, intravitreal aflibercept was administered bilaterally 
with further reduction of central macular thickness observed. Visual acuity remained stable 
throughout. Conclusions: This is the first case report to demonstrate a reduction of RP-
associated CMO following intravitreal aflibercept, despite inadequate response to ranibi-
zumab on two separate occasions. Aflibercept may provide superior action to other anti-
VEGF medications due to its intermediate size (115 kDa) and higher binding affinity. This is 
worthy of further investigation in a large prospective cohort over an extended time to de-
termine the safety and efficacy of intravitreal aflibercept for use in this condition. 
 © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Background 
Retinitis pigmentosa (RP) is the most prevalent inherited retinal disease (IRD), with IRD 
now representing the commonest cause of visual impairment registration in the working age 
population and the second commonest in childhood in the UK [1]. Typical symptoms of RP 
include nyctalopia, photopsia, and progressive visual field loss; however, vision can also be 
affected by cataracts and/or cystoid macular oedema (CMO).  
Around 20% of RP patients develop CMO, the pathogenesis of which is not clearly un-
derstood. Suggested mechanisms include: anti-retinal antibodies [2], retinal pigment epithe-
lium dysfunction [3], Muller cell oedema [4], and vitreous traction [5].  
Many treatments have been attempted for RP-associated CMO, including grid laser, 
vitrectomy, oral lutein, intravitreal dexamethasone, intravitreal triamcinolone, topical car-
bonic anhydrase inhibitors, oral carbonic anhydrase inhibitors, oral corticosteroids, topical 
non-steroidal anti-inflammatory medication, and topical steroid [6–10]. However, all of the 
aforementioned treatments have limited and highly variable efficacy. This, together with 
several side effects of these medications that markedly restrict their use, has led to the 
search to find alternative therapies that are both well tolerated and are more consistently 
effective.  
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) medication is now li-
cenced for use within the UK for CMO secondary to macular degeneration, diabetic retinopa-
thy, and retinal vein occlusion. While the pathogenesis of RP-associated CMO is still unclear, 
it is believed that VEGF may play a role in the development of CMO. It has therefore been 
suggested as an alternative treatment for RP-associated CMO. 
Limited data has been published regarding the use of intravitreal anti-VEGF medication 
for RP-associated CMO. Querques et al. [11] observed improvement of visual acuity and 
macular thickness in a patient with refractory RP-associated CMO taking oral acetazolamide, 
1 month following a single injection of intravitreal pegaptanib (MACUGEN; EyeTech Phar-
maceutical, Inc., New York, N.Y., USA). No recurrence of CMO was seen at 4 months post-
injection [11]. Melo et al. [12] observed no improvement in 2 patients with RP-associated 
CMO treated with a single injection of intravitreal bevacizumab (AVASTIN; Genentech, South 
San Francisco, Calif., USA); however, Yuzbasioglu et al. [13] documented improvement of 
macular thickness and visual acuity in all 13 eyes of 7 patients.  
Artunay et al. [14] treated 15 eyes with RP-associated CMO with intravitreal ranibi-
zumab and compared them with 15 eyes of similar patients who refused treatment. A signif-
icant improvement in macular thickness was observed in those patients treated with intravi-
treal ranibizumab.  
D
ow
nl
oa
de
d 
by
: 
UC
L 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
12
8.
41
.6
1.
54
 - 
8/
9/
20
17
 6
:0
4:
04
 P
M
 Case Rep Ophthalmol 2016;7:389–397 
DOI: 10.1159/000448427 © 2016 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cop 
Strong et al.: Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema 
Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab 
(Lucentis): A Case Report 
 
 
 
 
391 
In a recent case report, a single unilateral intravitreal injection of aflibercept was given 
to a patient with RP-associated CMO. Improvement in both visual acuity and macular thick-
ness was seen at 1 month post-injection as well as maintenance of this improvement docu-
mented at 6 months [15]. Aflibercept is a recombinant fusion protein consisting of portions 
of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of 
human IgG1. This unique design is what sets aflibercept apart from other intravitreal anti-
VEGF medications by enabling its action as a decoy receptor. 
Case Presentation 
In August 2013, a 38-year-old man from Dubai, United Arab Emirates, was seen by a 
medical retina specialist in the UK. He was previously diagnosed with autosomal recessive 
RP in Dubai and bilateral CMO had been documented over the last 3 years. The patient had 
undergone uncomplicated bilateral cataract surgery with the insertion of posterior chamber 
intraocular lenses in 2004. There was no other relevant past medical history. Family history 
revealed parental consanguinity, with his parents being first cousins.  
He had previously received topical dorzolamide and a 3-week trial of oral acetazolamide 
(Diamox) 250 mg three times per day, with no significant improvement in the degree or 
extent of CMO. Bilateral injections of ranibizumab (LUCENTIS; Genentech, South San Fran-
cisco, Calif., USA) had been performed once a month for 3 months in Dubai in 2013 with only 
minimal response observed. At the time of the consultation in the UK, the patient was no 
longer receiving topical or oral treatment for CMO. 
On examination, BCVA was 6/18 in the right eye and 6/36 in the left eye. Visual field 
testing to confrontation revealed constricted fields of 10–20 degrees in both eyes. Fundos-
copy revealed bilateral dense bone spicules, bilateral CMO, attenuated retinal vessels, and 
pale optic discs. Spectral domain optical coherence tomography (SDOCT) showed marked 
bilateral CMO with central macular thickness (CMT) of 394 and 414 μm in the right and left 
eye, respectively (fig. 1A, E).  
The anti-VEGF medication selected for use in this patient was aflibercept (EYLEA; Re-
generon Pharmaceuticals, Inc., Tarrytown, New York, N.Y., USA, and Bayer Healthcare Phar-
maceuticals, Berlin, Germany). This was due to there being only a minimal response ob-
served following treatment with ranibizumab as well as consideration that its effects may be 
longer lasting than other anti-VEGF medication. The risks and benefits of treatment with 
aflibercept together with its off-label use were discussed with the patient. It was also high-
lighted that there was a limited evidence base for its usage in RP-associated CMO.  
Informed consent was taken and bilateral intravitreal injections of 0.05 ml aflibercept 
(40 mg/ml) given via standard aseptic technique. There were no peri-operative complica-
tions. Post-operative chloramphenicol drops were prescribed. 
One month after treatment, BCVA improved to 6/12 in the right eye but remained 6/36 
in the left eye. The patient did not notice any subjective improvement. SDOCT revealed 
markedly less CMO in both eyes, with CMT of 263 and 243 μm in the right and left eye, re-
spectively (fig. 1B, F). A second uncomplicated intravitreal injection of aflibercept was un-
dertaken bilaterally. 
One month after his second injection of aflibercept, BCVA remained at 6/12 in the right 
eye and 6/36 in the left eye. At this visit, the patient reported a subjective improvement of 
vision. SDOCT revealed a similar level of CMO bilaterally compared to the previous visit. CMT 
was 268 and 239 μm in the right and left eye, respectively (fig. 1C, G).  
D
ow
nl
oa
de
d 
by
: 
UC
L 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
12
8.
41
.6
1.
54
 - 
8/
9/
20
17
 6
:0
4:
04
 P
M
 Case Rep Ophthalmol 2016;7:389–397 
DOI: 10.1159/000448427 © 2016 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cop 
Strong et al.: Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema 
Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab 
(Lucentis): A Case Report 
 
 
 
 
392 
The patient then returned to the United Arab Emirates where he was seen by a medical 
retina specialist in Dubai, in December 2013. BCVA was 6/18 in the right eye and 6/24 in the 
left eye. SDOCT revealed a similar level of CMO bilaterally (fig. 1D, H), despite his last afliber-
cept injection being 8 weeks prior. CMT was recorded as 253 and 224 μm in the right and 
left eye, respectively. As the patient was stable, the decision was taken not to treat with an 
alternative anti-VEGF, since aflibercept was due to be made available for use in Dubai from 
January 2014. 
Unfortunately, there was an unexpected delay in aflibercept being made available for 
use in Dubai. In March 2014 (5 months after the patient’s last injection of aflibercept), BCVA 
was 6/18 in the right eye and 6/36 in the left eye. SDOCT revealed a significant increase of 
CMO bilaterally, with CMT of 385 and 434 μm in the right and left eye, respectively (fig. 2A, 
C). In order not to delay treatment any further, the decision was taken to perform 3 monthly 
loading doses of ranibizumab bilaterally. The response to ranibizumab was markedly less 
pronounced compared to aflibercept. In May 2014, BCVA remained at 6/18 in the right eye 
and had decreased to 6/48 in the left eye. SDOCT revealed bilateral CMO, with CMT of 304 
and 342 μm in the right and left eye, respectively (fig. 2B, D). The decision was taken not to 
perform further injections of ranibizumab. 
In August 2014, the patient had an increased amount of CMO. SDOCT measured 452 and 
513 μm in the right and left eye, respectively (fig. 3A, E). Fortunately, aflibercept became 
available for use in Dubai, and the patient received treatment with 3 monthly loading doses 
of aflibercept bilaterally. A good response was noted once again. In October 2014, BCVA had 
improved to 6/18 in the right eye and 6/36 in the left eye. SDOCT showed a marked reduc-
tion in CMO (fig. 3B, F), measuring 248 and 226 μm in the right and left eye, respectively. 
The patient continued to receive aflibercept injections in January 2015, March 2015, 
June 2015, and September 2015 and CMT remained stable (fig. 3C, G). In September 2015, 
BCVA was 6/15 in the right eye, 6/36 in the left eye, with stable CMT of 250 and 194 μm in 
the right and left eye, respectively (fig. 3D, H). Figure 4 summarises the effect of anti-VEGF 
medications on CMT over time. 
Conclusions 
There are currently no proven treatments for RP-associated CMO. The use of medica-
tion, such as carbonic anhydrase inhibitors, has demonstrated inconsistent efficacy and un-
wanted side effects. FDA approval of anti-VEGF medication has now extended to include 
CMO secondary to age-related macular degeneration, diabetic retinopathy, and retinal vein 
occlusion. While the pathogenesis of RP-associated CMO is not entirely understood, VEGF 
may play a role in the formation of RP-associated CMO thereby representing a potential tar-
get for treatment. RP is not an ischaemic condition and if anything, the natural bone spicule 
formation secondary to photoreceptor cell death results in an overall reduction of oxygen 
consumption by the retina. We hypothesise that a localised source of VEGF produced, for 
example, by Muller cells under pathological conditions contributes to CMO formation whilst 
also explaining why it is rare to find reports of peripheral neovascularisation in RP.  
This is the first case report to demonstrate a reduction of RP-associated CMO following 
intravitreal aflibercept, despite inadequate response to ranibizumab. Aflibercept may pro-
vide superior action to other anti-VEGF medications due to its intermediate size (115 kDa) 
and higher binding affinity. This is worthy of further investigation in a large prospective 
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cohort over an extended time to determine the safety and efficacy of aflibercept for use in 
this condition. 
Statement of Ethics 
The patient has given his informed consent for this case report to be written. 
Disclosure Statement 
Funding was not received to write this case report; however, Bayer Plc will be ap-
proached to cover the publication costs should this article be accepted. 
The authors S.A.S. and M.M. declare that they are currently being funded by Bayer Plc. to 
set up a phase II exploratory trial at Moorfields Eye Hospital, London, UK, to review the safe-
ty and efficacy of aflibercept for RP-associated CMO. 
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Fig. 1. OCT of both eyes before and after intravitreal injections of aflibercept given in the UK. OCT in the 
right eye before injection of aflibercept (A), 1 month after the first injection of aflibercept (B), 1 month 
after the second injection of aflibercept (C), and 8 weeks after the third injection of aflibercept (D). OCT in 
the left eye before injection of aflibercept (E), 1 month after the first injection of aflibercept (F), 1 month 
after the second injection of aflibercept (G), and 8 weeks after the third injection of aflibercept (H). 
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Fig. 2. OCT of both eyes before and after intravitreal injections of ranibizumab given in Dubai. OCT in the 
right eye immediately before injection of ranibizumab (A) and on the day he received his third injection of 
ranibizumab (C). OCT in the left eye immediately before injection of ranibizumab (B) and on the day he 
received his third injection of ranibizumab (D). 
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Fig. 3. OCT of both eyes before and after intravitreal injections of aflibercept given in Dubai. OCT in the 
right eye immediately before injection of aflibercept (A), immediately before the third injection of afliber-
cept (B), 2 months following the fourth injection of aflibercept (C), and 3 months following the sixth injec-
tion of aflibercept (D). OCT in the left eye immediately before injection of aflibercept (E), immediately be-
fore the third injection of aflibercept (F), 2 months following the fourth injection of aflibercept (G), and 3 
months following the sixth injection of aflibercept (H). 
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Fig. 4. The effect of anti-VEGF medications on CMT over time is presented. 
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